TICKERNERD
Menu
PETSPETSHealthcare · Pharmaceutical Retailers

PETS Stock Forecast: PetMed Express, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.75
−0.57% on the day

The 1 Wall Street analysts covering PetMed Express, Inc. hold a median 12-month price target of $2.15 — +22.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$38.2M
Ticker Nerd rank
40 / 100
Median analyst target
$2.15
Analysts covering
1
Revenue$42.8M−19.2% y/y
Operating income−$5.7M
Net income−$4.1M
Free cash flow−$5.5M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
0.0%
1M
−12.1%
YTD
−45.3%
1Y
−44.3%
From 52W high
−55.1%
From 52W low
+9.4%
$1.60
$3.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PETS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PetMed Express, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Accruals
78
Issuance
67
Quality
46
Momentum
43
Volatility
37
Growth
30
Value
29
Revisions
25

Size (85): Smaller than most of the companies we track.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PETS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PETS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.50$2.00$2.50$3.00$3.50$4.00Oct 25Jan 26Apr 26Jul 26PETSHigh $2.15Median $2.15Low $2.15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy0 Hold1 Sell
Low $2.15Median $2.15High $2.15

The green dot is the last close — the median target sits +22.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Apr 2025Morgan StanleyMaintainsUnderweight$3.50 → $3.20
7 Aug 2024Lake StreetDowngradeHold—
12 June 2024Lake StreetMaintainsBuy—
12 June 2024Morgan StanleyMaintainsUnderweight—
16 Nov 2023Morgan StanleyMaintainsUnderweight—
31 Oct 2023Morgan StanleyMaintainsUnderweight—
19 Oct 2023Morgan StanleyMaintainsUnderweight—
27 July 2023Morgan StanleyReiteratesUnderweight—
25 May 2023Lake StreetInitiatesBuy—
23 Mar 2023Morgan StanleyMaintainsUnderweight—
8 Nov 2022Morgan StanleyMaintainsUnderweight—
26 July 2022Morgan StanleyMaintainsUnderweight—
10 May 2022Morgan StanleyMaintainsUnderweight—
25 Jan 2022Morgan StanleyMaintainsUnderweight—
20 Jan 2022Sidoti & Co.UpgradeBuy—
18 Nov 2021Morgan StanleyInitiatesUnderweight—
1 Oct 2021JefferiesInitiatesHold—
3 June 2021Sidoti & Co.DowngradeNeutral—
5 Mar 2021Sidoti & Co.UpgradeBuy—
19 Aug 2020Sidoti & Co.UpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PETS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PETS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, PetMed Express, Inc. returned −44.3% against +19.6% for the S&P 500, dividends included.

PETS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26PETSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PETS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+600.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

PetMed Express, Inc. (PETS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
257.0×

Cheaper than 3% of US stocks

Price / sales
0.2×

Cheaper than 92% of US stocks

Price / book
1.7×

Cheaper than 53% of US stocks

EV / EBITDA
−1.3×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
−19.9%

Higher than 11% of US stocks

Earnings growth (YoY)
−19.2%

Higher than 20% of US stocks

Gross margin
32.6%

Higher than 38% of US stocks

Operating margin
−15.2%

Higher than 23% of US stocks

Net margin
−17.3%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−78.6%

Higher than 16% of US stocks

Return on assets
−20.0%

Higher than 19% of US stocks

Dividend yield
67.8%

Higher than 98% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PetMed Express, Inc. (PETS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PetMed Express, Inc. has a market value of $38.2M and an enterprise value of $24.4M.

  • Revenue in the twelve months to 31 Mar 2026: $179.0M. The latest quarter shrank 19.9% year on year.

  • Net income over the same four quarters: −$57.3M, a −32.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.75.

  • Free cash flow in the twelve months to 31 Mar 2026: −$33.0M, after $4.6M of capital spending.

  • PetMed Express, Inc. spent $21K on dividends in the twelve months to 31 Mar 2026.

  • Shares outstanding: 21.4M.

  • Trailing P/E: 257.0×; forward P/E: −58.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 67.80%, paying out 0% of earnings.

  • PetMed Express, Inc. employs 189 people — $947K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

PETS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPharmaceutical Retailers
CompanyMarket capTKN rank
PETSPetMed Express, Inc.$38.2M
40
SCNXScienture Holdings, Inc.$18.3M
8
HITIHigh Tide, Inc.$213.8M
73
CCELCryo-Cell International, Inc.*$36.8M
75
SNWVSANUWAVE Health, Inc.*$39.5M
51
CRVOCervoMed, Inc.*$39.6M
29
ONMDOneMedNet Corp.*$35.6M
17

* Nearest Healthcare names by size — few pharmaceutical retailers companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PetMed Express, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PETS news & analysis

PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y

Zacks Investment Research · 14 Aug 2026negative

PetMed Express reported fiscal first-quarter 2027 results that missed estimates, with sales declining year over year. The company noted signs of progress through lower costs, stronger recurring sales, and new partnerships.

Why it matters — A PETS watcher would care because the earnings miss and year-over-year sales decline are notable even as the company points to cost reductions and growth in recurring sales and partnerships.

PetMed (PETS) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research · 13 Aug 2026negative

PetMed Express reported a fiscal first-quarter loss of $0.28 per share, wider than the $0.12 Zacks Consensus Estimate but narrower than the $0.34 per-share loss a year earlier. The company also missed revenue estimates for the quarter.

Why it matters — PETS watchers would track this because the miss on Wall Street's earnings and revenue estimates signals weaker-than-expected performance for the company's latest quarter.

PetMed Express, Inc. (PETS) Q1 2027 Earnings Call Prepared Remarks Transcript

Seeking Alpha · 13 Aug 2026neutral

PetMed Express, Inc. (PETS) released a transcript of its prepared remarks from its Q1 2027 earnings call. The excerpt provides only the headline and source listing for the transcript.

Why it matters — The earnings call transcript offers investors insight into PetMed Express's most recent quarterly performance and management commentary.

PetMeds® Announces First Quarter Financial Results

GlobeNewsWire · 13 Aug 2026neutral

PetMed Express, Inc. (dba PetMeds, parent of PetCareRx) announced its financial results for the first quarter ended June 30, 2026. The announcement was made on August 13, 2026 via GlobeNewsWire.

Why it matters — This is the company's quarterly financial report, which PETS investors would watch for visibility into its recent performance.

PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026

GlobeNewsWire · 30 July 2026neutral

PetMed Express, Inc. announced it will report its first quarter fiscal year 2027 financial results after market close on Thursday, August 13, 2026, followed by a conference call and webcast at 4:30 p.m. Eastern Time that same day.

Why it matters — The announcement sets the date for the company's next quarterly earnings release, which investors and analysts tracking PETS will watch for updates on financial performance and business trends.

FAQ

Frequently asked questions about PETS stock

What is the PETS stock price forecast for 2026-2027?

The 1 Wall Street analysts covering PetMed Express, Inc. have a median 12-month price target of $2.15, with estimates ranging from $2.15 to $2.15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PETS stock a buy right now?

Of the 1 analysts covering PetMed Express, Inc., 0 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PetMed Express, Inc. 40 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PETS?

As at 22 Aug 2026, PetMed Express, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will PETS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +22.9% from the last close, and Ticker Nerd's factor model ranks PetMed Express, Inc. 40 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PETS stock forecast for 2030?

No analyst covering PetMed Express, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PETS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.15 to $2.15 over the next 12 months.

How has PETS stock performed over the past year?

PetMed Express, Inc. returned -44.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PetMed Express, Inc. do?

PetMed Express Inc. is a leading retailer in the pet medication and health products industry.

What is the latest news on PETS?

The most recent item we track (Zacks Investment Research, 14 Aug 2026): "PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y". PetMed Express reported fiscal first-quarter 2027 results that missed estimates, with sales declining year over year. The company noted signs of progress through lower costs, stronger recurring sales, and new partnerships.

Company

About PetMed Express, Inc.

PetMed Express Inc. is a leading retailer in the pet medication and health products industry. The company specializes in delivering prescription and non-prescription pet medications directly to customers, predominantly serving the pet owners' market in the United States. PetMed Express offers a variety of products for dogs, cats, and small pets, including prescription and non-prescription medications, health supplies, and nutritional supplements. Through its platform, 1-800-PetMeds, it aims to provide pet owners with a convenient, cost-effective alternative to purchasing veterinary medications. The company plays a vital role in the burgeoning pet care industry, which continues to grow as pet ownership becomes more prevalent. Founded in 1996 and headquartered in Florida, PetMed Express frequently emphasizes the importance of accessibility to high-quality pet care products. Its business model combines e-commerce and personalized customer service, positioning itself as a key player in meeting the demands of pet health care in modern lifestyles.

CEO Ms. Leslie C. G. Campbell · 189 employees · United States · https://www.1800petmeds.com